Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2024; 30(46): 4964-4968
Published online Dec 14, 2024. doi: 10.3748/wjg.v30.i46.4964
Fanlian Huazhuo Formula: A promising herbal preparation for metabolic liver disease
Bhupesh Singla
Bhupesh Singla, Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, TN 38103, United States
Author contributions: Singla B wrote, edited, and proofread the article.
Supported by the National Institutes of Health Grants, No. K99HL146954 and No. R00HL146954; and the College of Pharmacy Seed Research Grant Program of the University of Tennessee Health Science Center.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bhupesh Singla, Assistant Professor, PhD, Pharmaceutical Sciences, The University of Tennessee Health Science Center, 881 Madison Ave, Room 446, Memphis, TN 38103, United States. bsingla@uthsc.edu
Received: August 28, 2024
Revised: October 17, 2024
Accepted: November 5, 2024
Published online: December 14, 2024
Processing time: 85 Days and 15.9 Hours
Core Tip

Core Tip: Various constituents of Fanlian Huazhuo Formula (FLHZF) have been shown to regulate several metabolic and inflammatory parameters in diabetic mice, including hepatic lipid metabolism and injury, body weight, adipose tissue inflammation, and gut microbiota. Niu et al reported novel insights into the therapeutic benefits of FLHZF in diet-induced metabolic dysfunction-associated steatotic liver disease using various complementary approaches. However, future studies are required to better understand the underlying molecular mechanisms, determine the therapeutic efficacy of FLHZF in other models, and rule out its sex-specific benefits.